Asan Medical center

Site:	Asan Medical center
Address:
City:	Seoul
State:	Songpa-gu
Zip:	05505
Country:	Republic of Korea

27 trials at this site

Phase	Trial	Trial Status	Site Status [desc]	Drug	NCT#
2	A Phase II Study of Oral Paclitaxel (Liporaxel) in GIST Patients With a Low P-glycoprotein Expression After Failure With Imatinib, Sunitinib and Regorafenib	Not yet recruiting	Not yet activated	Liporaxel	NCT06326346
1	Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors	Withdrawn	Not yet activated	Imatinib + Dovitinib	NCT02268435
1/2	PDR001 Plus Imatinib for Metastatic or Unresectable GIST	Completed	Closed	Imatinib + PDR001	NCT03609424
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	Rechallenge of Imatinib in GIST Having no Effective Treatment (RIGHT)	Completed	Closed	Imatinib	NCT01151852
3	L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors	Completed	Closed	L-carnitine	NCT03426722
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Active, not recruiting	Closed	Ripretinib	NCT05734105
2	REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response	Completed	Closed	Imatinib, Nilotinib
2	Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation	Active, not recruiting	Closed	Imatinib	NCT01541709
2	Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib	Completed	Closed	Regorafenib (BAY 73-4506)	NCT02889328
1	A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	Cobimetinib + MPDL3280A	NCT01988896
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors	Active, not recruiting	Closed	IDRX-42	NCT05489237
	Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	Nilotinib	NCT00976612
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Active, not recruiting	Active, not recruiting	Bezuclastinib plus Sunitinib	NCT05208047
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)	Recruiting	Active	Velzatinib	NCT07585266
2	Dovitinib for Imatinib/Sunitinib-failed Gastrointestinal Stromal Tumors (GIST)	Completed	Active	Dovitinib	NCT01440959

Asan Medical center

27 trials at this site

Page 1 of 2 | Next | Last